Royal Sense Ltd
Incorporated in 2023, Royal Sense Ltd specializes in medical device and pharmaceutical trading.[1]
- Market Cap ₹ 63.9 Cr.
- Current Price ₹ 119
- High / Low ₹ 310 / 85.0
- Stock P/E 8.94
- Book Value ₹ 75.7
- Dividend Yield 0.00 %
- ROCE 26.2 %
- ROE 21.0 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| 18 | 62 | 103 | |
| 16 | 53 | 92 | |
| Operating Profit | 2 | 9 | 11 |
| OPM % | 13% | 14% | 11% |
| 0 | 0 | 0 | |
| Interest | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | 2 | 9 | 10 |
| Tax % | 28% | 27% | 28% |
| 2 | 6 | 7 | |
| EPS in Rs | 3.24 | 12.74 | 13.36 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 67% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 13% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -44% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 20% |
| Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Equity Capital | 5 | 5 | 5 |
| Reserves | 13 | 23 | 35 |
| 2 | 3 | 13 | |
| 1 | 5 | 8 | |
| Total Liabilities | 21 | 36 | 61 |
| 0 | 2 | 2 | |
| CWIP | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| 20 | 33 | 59 | |
| Total Assets | 21 | 36 | 61 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| -4 | 1 | -13 | |
| -1 | -2 | -0 | |
| 13 | 3 | 5 | |
| Net Cash Flow | 9 | 2 | -8 |
| Free Cash Flow | -4 | -0 | -14 |
| CFO/OP | -144% | 21% | -110% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|
| Debtor Days | 66 | 86 | 101 |
| Inventory Days | 63 | ||
| Days Payable | 10 | ||
| Cash Conversion Cycle | 66 | 86 | 153 |
| Working Capital Days | 187 | 86 | 126 |
| ROCE % | 35% | 26% |
Insights
In beta| Mar 2024 | Mar 2025 | |
|---|---|---|
| Geographic Presence (States/UTs) count ・Standalone data |
|
|
| Permanent Employees count ・Standalone data |
||
| New Products Launched count ・Standalone data |
||
| Satisfied Customers count ・Standalone data |
||
| Total Product Portfolio count ・Standalone data |
||
| US FDA Approvals Obtained count ・Standalone data |
||
Extracted by Screener AI
Documents
Announcements
- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011. 4 Jul
-
Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
27 Jun - Prachi Agnihotri resigned as Company Secretary and Compliance Officer effective close of business 27 June 2026.
-
Financial Results For The Year Ended 31St March, 2026
25 May - Board approved audited standalone and consolidated FY26 results, ESOP revision, committees, and director remuneration on 25 May 2026.
-
Board Meeting Outcome for Disclosures Pursuant To The Provisions Of Regulation 30 Of SEBI (Listing Obligation & Disclosure Requirements) Regulation, 2015 Read With Para-A Part-A Of Schedule III_ Submission Of The Outcome Of Board Meeting Of The Company.
25 May - Board approved audited FY26 standalone/consolidated results, ESOP term revision, committees, and director remuneration on 25 May 2026.
-
Non-Applicability Of The Submission Of Annual Secretarial Compliance Report Under Regulation 24A(2) Of SEBI (LODR) Regulation, 2015.
22 May - Royal Sense says FY26 Annual Secretarial Compliance Report is not applicable under SME exemption.
Business Overview:[1][2]
RSL deals in Advanced medical devices, pharmaceuticals, diagnostics, and offers surgical solutions. It provides hospitals, laboratories, clinics, and institutions
with products like surgical accessories, instruments, equipment, consumables,
reagents, diagnostic kits, and disposable
medical supplies